MedTrace Logo

FASHION Fabry Disease Hypertrophic Cardiomyopathy and Infammation

NCT05761834 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-03-09

No results posted yet for this study

Summary

In Fabry disease (FD) and hypertrophic cardiomyopathy (HCM) systemic inflammation recently gained attention as a possible key pathophysiologic process involved in the development of cardiac hypertrophy and progression of the disease. Differences in inflammatory profile between FD and HCM have never been investigated so far.

Conditions

Interventions

OTHER

Sample blood and 2D-echocardiography with Doppler

Investigate whether patients with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells.

Sponsors & Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-27
Primary Completion
2023-07-27
Completion
2025-01-10

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05761834 on ClinicalTrials.gov